Skip to main content
Download PDF

Investigation of gyrA and parC mutations and the prevalence of plasmid-mediated quinolone resistance genes in Klebsiella pneumoniae clinical isolates

BMC Microbiology volume 24, Article number: 265 (2024) Cite this article

Abstract

Background

The emergence of fluoroquinolone resistance in clinical isolates of Klebsiella pneumoniae is a growing concern. To investigate the mechanisms behind this resistance, we studied a total of 215 K. pneumoniae isolates from hospitals in Bushehr province, Iran, collected between 2017 and 2019. Antimicrobial susceptibility test for fluoroquinolones was determined. The presence of plasmid mediated quinolone resistance (PMQR) and mutations in quinolone resistance-determining region (QRDR) of gyrA and parC genes in ciprofloxacin-resistant K. pneumoniae isolates were identified by PCR and sequencing.

Results

Out of 215 K. pneumoniae isolates, 40 were resistant to ciprofloxacin as determined by E-test method. PCR analysis revealed that among these ciprofloxacin-resistant isolates, 13 (32.5%), 7 (17.5%), 40 (100%), and 25 (62.5%) isolates harbored qnrB, qnrS, oqxA and aac(6’)-Ib-cr genes, respectively. Mutation analysis of gyrA and parC genes showed that 35 (87.5%) and 34 (85%) of the ciprofloxacin-resistant isolates had mutations in these genes, respectively. The most frequent mutations were observed in codon 83 of gyrA and codon 80 of parC gene. Single gyrA substitution, Ser83→ Ile and Asp87→Gly, and double substitutions, Ser83→Phe plus Asp87→Ala, Ser83→Tyr plus Asp87→Ala, Ser83→Ile plus Asp87→Tyr, Ser83→Phe plus Asp87→Asn and Ser83→Ile plus Asp87→Gly were detected. In addition, Ser80→Ile and Glu84→Lys single substitution were found in parC gene.

Conclusions

Our results indicated that 90% of isolates have at least one mutation in QRDR of gyrA orparC genes, thus the frequency of mutations was very significant and alarming in our region.

Peer Review reports

Background

Fluoroquinolones (FQs) are commonly used as effective antibiotics for the treatment of most infections caused by Gram-negative bacteria [1]. Unfortunately, due to their extensive use, FQ resistance (FQ-R) is on the rise in clinically important bacteria, including Klebsiella pneumoniae [1, 2]. FQs inhibit the activity of DNA gyrase and topoisomerase IV enzymes, which are essential enzymes for bacterial DNA replication and survival [2]. The main mechanisms of resistance to FQs in Enterobacteriaceae arise from chromosomal mutations in the quinolone resistance-determining region (QRDR), particularly of gyrA and parC encoding DNA gyrase, and topoisomerase IV, respectively. These mutations lead to structural changes in DNA gyrase and/or topoisomerase IV, which impairs the affinity to FQs [3]. Plasmid-mediated quinolone resistance (PMQR) genes are alternative mechanism of quinolone resistance. However, PMQR has been shown to emerge even in the absence of FQ therapy [4]. Three types of PMQR determinants have been identified in Enterobacteriaceae: (i) Qnr proteins, encoded by qnr genes (qnrA, qnrB, qnrC, qnrD and qnrS), belong to the pentapeptide repeat family and protect DNA gyrase and topoisomerase IV from quinolone inhibition by binding to them [1, 5]. (ii) The AAC(6’)-Ib-cr enzyme, a variant aminoglycoside acetyltransferase encoded by aac(6’)-Ib-cr gene, can modify ciprofloxacin with a piperazinyl substituent, reducing its activity [6]. (iii) OqxAB and QepA pumps reduce susceptibility to FQs by drug extrusion from the cell. These multidrug efflux pumps belong to the resistance–nodulation–cell division (RND) family and the major facilitator superfamily (MFS), respectively [2, 7]. The patterns of resistance mechanisms to FQ vary across different countries due to geographical impact on the emergence and dissemination of FQ-R mechanisms [1]. Thus, it is important to determine the major FQ-R mechanisms in each geographical area. The aim of this study was to determine chromosomal mutations in gyrA and parCgenes as well as the prevalence of PMQR genes among fluoroquinolone resistant K. pneumoniae isolates in Bushehr province, Iran.

Methods

Bacterial isolation and identification

This project was approved by the Ethical Committee of Bushehr University of Medical Sciences with reference number IR.BPUMS.REC.1400.133. A total of 215 K. pneumoniae isolates were collected from six hospitals located in Bushehr province, in the south of Iran from November 2017 to February 2019. Bacterial identification was conducted by biochemical tests and confirmed by PCR to target malate dehydrogenase (mdh), the genus-specific housekeeping gene (Table 1) [8,9,10].

Table 1 Oligonucleotide primers used for detection PMQR determinants and mutation in QRDR
Full size table

Antimicrobial susceptibility testing

Antimicrobial susceptibility testing was determined by disk diffusion method for ciprofloxacin (5 mg) and levofloxacin (5 mg) in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines [18]. In addition, MIC of ciprofloxacin was determined using E-tests (Liofilchem, Italy) on Mueller-Hinton agar (Biolife, Italy). Escherichia coli ATCC 25922 was used as the control strain for the antibiotic susceptibility tests.

Detection of plasmid-mediated quinolone resistance genes

Plasmid-mediated quinolone resistance genes, including qnrA, qnrB, qnrC, qnrD, qnrS, aac(6’)-Ib-cr, oqxA, and qepA in ciprofloxacin-resistant isolates, were detected by PCR and sequencing performed by Bioneer Company (South Korea). The primers and PCR conditions used in this study were listed in Table 1.

Detection of mutations in QRDR of gyrA and parC genes

A total of 40 ciprofloxacin-resistant isolates were selected. PCR amplification of gyrA and parC genes were carried out using primers and conditions listed in Table 1. A total reaction volume of 25 µl contained 12.5 µl 2x MasterMix (Ampliqon, Odense, Denmark), 1 µl (10 µmol) of each forward and reverse primer, 1 µl of template DNA; and 9.5 µl of nuclease-free water. The amplification conditions were as follows: pre-denaturation at 95 °C for 5 min; 30 cycles of denaturation at 94 °C for 1 min, annealing at 60 °C/59°C (gyrA / parC) for 30 s, and extension at 72 °C for 30 s, followed by a final extension at 72 °C for 5 min. Nucleotide sequencing of the PCR products was performed by the Bioneer Company (Seoul, Korea). Mutations in gyrA and parC genes for the 40 ciprofloxacin-resistant K. pneumoniae isolates were compared with the reference sequences of gyrA gene of K. pneumoniae ATCC13883 (GenBank accession number: DQ673325) and parC gene of K. pneumoniae ATCC1388T (GenBank accession number: AF303641). Online sequence alignment and analysis were performed using the online ClustalW2 multiple sequence alignment program.

Nucleotide sequence accession number

The sequences of detected genes were submitted to the GenBank database under accession numbers OQ281591 - OQ281600.

Results

FQ susceptibility

Antimicrobial susceptibility testing (AST) revealed that among 215 of K. pneumoniae clinical isolates, 49 isolates (22.7%) were resistant to ciprofloxacin disk, 15 isolates (7%) were intermediate, and 151 isolates (70.2%) were susceptible in disk diffusion method. Moreover, among 64 isolates not susceptible to ciprofloxacin, 31, 7 and 26 isolates were resistant, intermediate, and susceptible to levofloxacin disk, respectively. In addition, out of 49 ciprofloxacin-resistant isolates, 40 isolates were resistant by E-test strips (MIC ≥ 4 µg/ml). These 40 ciprofloxacin-resistant isolates were selected for detection of PMQR genes and mutation in QRDR of gyrA and parC genes (Table 2).

Table 2 Antimicrobial susceptibility testing of quinolones, PMQR, and mutations in QRDR of gyrA and parC genes of 40 K. pneumoniae isolates
Full size table

Characterization of PMQR genes

Molecular analysis revealed all 40 (100%) ciprofloxacin-resistant isolates carried at least one PMQR determinant: 40 (100%), 13 (32.5%), 7 (17.5%), and 25 (62.5%) isolates harbored oqxA, qnrB, qnrS, and aac(6’)-Ib-cr genes, respectively. Therefore, the prevalence of PMQR genes in our ciprofloxacin-resistant K. pneumoniae clinical isolates was 100%. In this study qepA, qnrC, qnrD, and qnrA genes were not found. Notably, as shown in Table 2, coexistence of 2 and 3 PMQR genes was found in 23 (57.5%) and 12 (30%) ciprofloxacin-resistant isolates, respectively. The remaining 5 isolates only carried oqxA gene.

Mutations in QRDR of gyrA and parC genes

Analysis of mutations in gyrA and parC genes indicated that out of 40 ciprofloxacin-resistant K. pneumoniae isolates, 35 (87.5%) and 34 isolates (85%) had mutations in gyrA and parC genes, respectively. The most mutations were observed in Ser 83 of gyrA and Ser 80 of parC gene (Table 2). As shown in Table 3, single gyrA substitution including Ser83→ Ile and Asp87→Gly, and double gyrA substitutions including Ser83→Phe plus Asp87→Ala, Ser83→Tyr plus Asp87→Ala, Ser83→Ile plus Asp87→Tyr, Ser83→Phe plus Asp87→Asn, and Ser83→Ile plus Asp87→Gly were detected. The most common mutation in gyrA gene was Ser83→ Ile, which was present in 21 (52.5%) isolates. In addition, 14 isolates (35%) had double mutations in the gyrA gene (Table 3). Mutation analysis of parC gene indicated that the most common mutation in parC gene was Ser80→Ile, which was detected in 32 (80%) isolates. Moreover, 2 (5%) isolates had Glu84→Lys amino acid substitution in parC gene (Table 3).

Table 3 The frequency of mutations and amino acid changes within gyrA, and parC of 40 ciprofloxacin –resistant isolates
Full size table

Correlation of ciprofloxacin MIC values with mutations in the QRDRs of gyrA and parC genes

Notably, a significant correlation between the frequency of mutations in QRDR of gyrA and parC and ciprofloxacin MIC values was observed in the present study, as the results showed that 29 out of 31 isolates in which the MIC of ciprofloxacin was ≥ 32 µg/ml had 2 or 3 mutations in both gyrA and parC genes simultaneously, while in 4 resistant isolates in which the MIC of ciprofloxacin was equal to 4 µg/ml, two isolates had no mutations and the other two isolates had only one mutation in the gyrA gene. It is worth noting that there was no correlation between the MIC values of ciprofloxacin and the number of harbored PMQR genes.

Discussion

Fluoroquinolones, such as ciprofloxacin, are a group of effective drugs for the treatment of Klebsiella pneumoniae infections, which inhibit bacterial DNA replication by binding to topoisomerase IV and DNA gyrase enzymes [19]. Unfortunately, resistance to these antimicrobial agents has emerged, and the level of resistance is increasing due to their widespread use.

The main mechanism of resistance to FQs in bacteria is spontaneous mutations in the QRDR of gyrA gene encoding DNA gyrase and parC gene encoding topoisomerase IV, particularly at the highly conserved residues Ser83 and Asp87 of gyrA gene [20].

In the present study, we investigated mutations in the QRDR of gyrA and parC genes and the prevalence of PMQR genes among fluoroquinolone resistant K. pneumoniae clinical isolates.

Our results demonstrated that 18.6% of isolates were resistant to ciprofloxacin, which was in agreement with previous studies conducted by Jomehzadeh et al., (18.5%) [21], Razavi et al. (19.6%) [22], and Priyadarshini et al., (19.1%) [23]. In addition, 31 (77.5%) out of 40 resistant isolates showed high-level resistance (≥ 32 µg/ml) to ciprofloxacin. Different frequencies of high-level resistance were reported by Ghane et al., (18.5%), Esmaeel et al., (57.8%) [24], and Geetha et al., (88%) [25].

Although mutations in QRDR of gyrA and parC genes are the main cause of FQs resistance, PMQR genes contribute to fluoroquinolone resistance due to their high horizontal transferability [21].

Our molecular analysis identified that 40 (100%) ciprofloxacin-resistant isolates harbored at least one PMQR determinant and the most common PMQR gene among our isolates was oqxA gene (100%). Prevalence of PMQR genes in the study conducted by Jomehzadeh et al. [21] was 88% and aac(6’)-Ib-cr was detected as the most common PMQR gene (50%), while in another study done by Sani et al. 85.4% of the isolates harbored PMQR genes and the most prevalent PMQR gene was qnrS (41.67%) [26]. Furthermore, qnrA and qepA genes have not been reported in several studies conducted in some geographic areas, including Korea, Malaysia, and Iran which support our data for these genes [27, 28].

The main mechanism of resistance to FQ in the Enterobacteriaceae is alterations in QRDR of gyrA, which encodes DNA gyrase, a type II topoisomerase [29].

Mutation analysis in QRDR of gyrA gene revealed that 35(87.5%) out of 40 ciprofloxacin-resistant isolates had at least one mutation in gyrA gene and the most frequent amino acid substitution in gyrA gene was Ser83→Ile, which was found in 52.5% of our isolates. This finding was inconsistent with the studies done by Fu et al. (all ciprofloxacin-resistant isolates had Ser83→Leu or Ser83→ Ile substitutions) [29], and Azargun et al. (all ciprofloxacin-resistant isolates had Ser83→Leu substitution) [2]. However, it should be mentioned that in the present study among 6 isolates with low-level resistance to ciprofloxacin (MIC = 4–8 µg/ml) only one isolate had Ser83→Ile substitution. In addition, single substitution Ser83→Ile was detected in 19 (47.5%) ciprofloxacin-resistant isolates and 14 (35%) isolates had five types of double mutations at Ser83 and Asp87 positions. Fu et al. reported, among Ser83→Leu, Ser83→Ile, Ser83→Tyr, and Ser83→Phe single substitutions, only Ser83→Ile single substitution showed significantly different distribution between the ciprofloxacin-resistant and ciprofloxacin-susceptible isolates [29].

Additionally, Fu et al. reported out of eight types of double mutations involving both Ser83 and Asp87 only three double mutations including Ser83→Leu plus Asp87→Asn, Ser83→Phe plus Asp87→Asn, and Ser83→Tyr plus Asp87→Asn were associated with ciprofloxacin resistance [29]. In the study conducted by Azargun et al., Ser83→Leu plus Asp87→Asn double mutations were detected in 60% of FQ-resistant K. pneumoniae isolates [2]. In agreement with their findings, one of the five double mutations identified in our study was Ser83→Phe plus Asp87→Asn but the four remaining double mutations of the present study were not found in the Fu, and Azargun’s studies. Therefore, the effect of the other double mutations was ignored in the mentioned studies. It is notable that, in agreement with the present study, the most common double mutation observed in the Akya’s study was Ser83→Phe plus Asp87→Ala, which was present in 42.9% of FQ-resistant K. pneumoniae isolates [27]. Moreover, similar to the current study Ser83→Phe plus Asp87→Asn double mutations were detected in 14.3% of FQ-resistant K. pneumoniae isolates. However, the three remaining double mutations of the present study were not found in their study.

Although amino acid substitutions at other positions of gyrA QRDR including Glu94, Arg154, Thr161, Ala171, Gly177and Leu 187 were reported [27, 29], Anuar et al., indicated ciprofloxacin resistance was significantly associated with gyrA alteration in Ser83 (p = 0.003), Asp87 (p = 0.005) or both of them (p = 0.016) [30]. Supporting this finding in the present study, amino acid substitutions in QRDR of gyrA gene at positions other than Ser83 and Asp87 were not found. Another factor that affects resistance to FQ is mutation in the QRDR of parC gene. Mutation analysis of parC QRDR revealed that 34 (85%) isolates had mutations in parC gene including Ser80→Ile (80%) and Glu84→Lys (5%). In the studies done by Azargun et al., [2] 60%, and by Akya et al., [27] 53.6% of FQ-R K. pneumoniae isolates had Ser80→Ile amino acid substitutions. Moreover, in Akya’s study Glu84→Lys amino acid substitution was found in 25% of FQ-R K. pneumoniae isolates [27].

In addition, in our study 14 (35%) isolates had three mutations in QRDR of both gyrA and parC genes. Notably, the frequency of mutations in QRDR of gyrA and parC revealed a significant effect on ciprofloxacin MIC values; as the results showed 29 isolates out of 31 isolates in which the MIC of ciprofloxacin was ≥ 32 µg/ml had 2 or 3 mutations in both gyrA and parC genes simultaneously, while in 4 resistant isolates in which the MIC of ciprofloxacin was equal to 4 µg/ml, two isolates had no mutations and the other two isolates had only one mutation in the gyrA gene.

Conclusion

In conclusion, all ciprofloxacin-resistant K. pneumoniae isolates either had mutations in the QRDR of gyrA and parC genes or carried PMQR genes.  Our results showed 90% of ciprofloxacin-resistant K. pneumoniae isolates had at least one mutation in QRDR of gyrA orparC genes, thus the frequency of mutation in QRDR was very significant and alarming in our region. Amino acid substitution Ser83→Ile in gyrA which has the greatest impact on ciprofloxacin resistance and Ser80→Ile in parC genes were the most frequent mutations among our FQ-R K. pneumoniae isolates. In addition, acquisition of 2 or 3 mutations in both gyrA and parC genes played an important role in conferring high level resistance to ciprofloxacin.

Data availability

The sequences of detected genes were submitted to the GenBank database under accession numbers OQ281591 - OQ281600.

Abbreviations

PMQR:

Plasmid mediated quinolone resistance

QRDR:

Quinolone resistance-determining region

FQs:

Fluoroquinolones

RND:

Resistance–nodulation–cell division

MFS:

Major facilitator superfamily

References

  1. Zeng L, Zhang J, Li C, Fu Y, Zhao Y, Wang Y, Zhao J, Guo Y, Zhang X. The determination of gyrA and parC mutations and the prevalence of plasmid-mediated quinolone resistance genes in carbapenem resistant Klebsiella pneumonia ST11 and ST76 strains isolated from patients in Heilongjiang Province, China. Infect Genet Evol. 2020;82:104319. https://doi.org/10.1016/j.meegid.2020.104319

    Article  CAS  PubMed  Google Scholar 

  2. Azargun R, Barhaghi MHS, Kafil HS, Oskouee MA, Sadeghi V, Memar MY, Ghotaslou R. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan. Iran J Glob Antimicrob Resist. 2019;17:39–43. https://doi.org/10.1016/j.jgar.2018.11.003

    Article  PubMed  Google Scholar 

  3. Kareem SM, Al-Kadmy IM, Kazaal SS, Mohammed Ali AN, Aziz SN, Makharita RR, Algammal AM, Al-Rejaie S, Behl T, Batiha GE-S. Detection of gyrA and parC mutations and prevalence of plasmid-mediated quinolone resistance genes in Klebsiella pneumoniae. Infect Drug Resist. 2021;555–63. https://doi.org/10.2147/IDR.S275852

  4. Abdel-Rahim MH, El-Badawy O, Hadiya S, Daef EA, Suh S-J, Boothe DM, Aly SA. Patterns of fluoroquinolone resistance in Enterobacteriaceae isolated from the Assiut University Hospitals, Egypt: a comparative study. Microb Drug Resist. 2019;25:509–19. https://doi.org/10.1089/mdr.2018.0249

    Article  CAS  PubMed  Google Scholar 

  5. Salah FD, Soubeiga ST, Ouattara AK, Sadji AY, Metuor-Dabire A, Obiri-Yeboah D, Banla-Kere A, Karou S, Simpore J. Distribution of quinolone resistance gene (qnr) in ESBL-producing Escherichia coli and Klebsiella spp. in Lomé, Togo. Antimicrob Resist Infect Control. 2019;8:1–8. https://doi.org/10.1186/s13756-019-0552-0

    Article  CAS  Google Scholar 

  6. Jiang Y, Zhou Z, Qian Y, Wei Z, Yu Y, Hu S, Li L. Plasmid-mediated quinolone resistance determinants qnr and aac (6’)-Ib-cr in extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in China. J Antimicrob Chemother. 2008;61:1003–6. https://doi.org/10.1093/jac/dkn063

    Article  CAS  PubMed  Google Scholar 

  7. Ciesielczuk H, Hornsey M, Choi V, Woodford N, Wareham D. Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. J Med Microbiol. 2013;62:1823–7.

    Article  CAS  PubMed  Google Scholar 

  8. Latifi B, Tajbakhsh S, Ahadi L, Yousefi F. Coexistence of aminoglycoside resistance genes in CTX-M-producing isolates of Klebsiella pneumoniae in Bushehr province, Iran. Iran J Microbiol. 2021;13:161. https://doi.org/10.18502/ijm.v13i2.5975

    Article  PubMed  PubMed Central  Google Scholar 

  9. Barati A, Ghaderpour A, Chew LL, Bong CW, Thong KL, Chong VC, Chai LC. Isolation and characterization of aquatic-borne Klebsiella pneumoniae from tropical estuaries in Malaysia. Int J Environ Res Public Health. 2021;13:426. https://doi.org/10.3390/ijerph13040426

    Article  CAS  Google Scholar 

  10. Thong KL, Lai M, Teh CSJ, Chua KH. Simultaneous detection of methicillin-resistant Staphylococcus aureus, Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa by multiplex PCR. Tropcl Biomed. 2011;28:21–31.

    CAS  Google Scholar 

  11. Liao C-H, Hsueh P-R, Jacoby GA, Hooper DC. Risk factors and clinical characteristics of patients with qnr-positive Klebsiella pneumoniae bacteraemia. J Antimicrob Chemother. 2013;68:2907–14. https://doi.org/10.1093/jac/dkt295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Li B, Yi Y, Wang Q, Woo PC, Tan L, Jing H, Gao GF, Liu CH. Analysis of drug resistance determinants in Klebsiella pneumoniae isolates from a tertiary-care hospital in Beijing, China. 2012. https://doi.org/10.1371/journal.pone.0042280

  13. Xu G, An W, Wang H, Zhang X. Prevalence and characteristics of extended-spectrum β-lactamase genes in Escherichia coli isolated from piglets with post-weaning diarrhea in Heilongjiang province, China. Front Microbiol. 2015;6:1103. https://doi.org/10.3389/fmicb.2015.01103

    Article  PubMed  PubMed Central  Google Scholar 

  14. Rodríguez-Martínez JM, Machuca J, Cano ME, Calvo J, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone resistance: two decades on. Drug Resist Updates. 2016;29:13–29. https://doi.org/10.1016/j.drup.2016.09.001

    Article  Google Scholar 

  15. Sadek M, Soliman AM, Nariya H, Shimamoto T, Shimamoto T. Genetic characterization of carbapenemase-producing Enterobacter cloacae complex and Pseudomonas aeruginosa of food of animal origin from Egypt. Microb Drug Resist. 2021;27:196–203. https://doi.org/10.1089/mdr.2019.0405

    Article  CAS  PubMed  Google Scholar 

  16. Chen X, Zhang W, Pan W, Yin J, Pan Z, Gao S, Jiao. X.Prevalence of qnr, aac (6’)-Ib-cr, qepA, and oqxAB in Escherichia coli isolates from humans, animals, and the environment. Antimicrob Agents Chemother. 2012;56:3423–7. https://doi.org/10.1128/aac.06191-11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fatima S, Liaqat F, Akbar A, Sahfee M, Samad A, Anwar M, et al. Virulent and multidrug-resistant Klebsiella pneumoniae from clinical samples in Balochistan. Int Wound J. 2021;18:510–8. https://doi.org/10.1111/iwj.13550

  18. Wayne PA. Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing. 2018 M100, 28th ed.

  19. Tang K, Zhao H. Quinolone antibiotics: Resistance and Therapy. Infect Drug Resist. 2023;16:811–20. https://doi.org/10.2147/IDR.S401663

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Norouzi A, Azizi O, Hosseini H, Shakibaie S. Amino acid substitution mutations analysis of gyrA and parC genes in clonal lineage of Klebsiella pneumoniae conferring high-level quinolone resistance. J Med Microbiol Infec Dis. 2014;2:109–17.

    Google Scholar 

  21. Jomehzadeh N, Ahmadi K, Bahmanshiri MA. Investigation of plasmid-mediated quinolone resistance genes among clinical isolates of Klebsiella pneumoniae in southwest Iran. J Clin Lab Anal. 2022;36. https://doi.org/10.1002/jcla.24342

  22. Razavi S, Mirnejad R, Babapour E. Involvement of AcrAB and OqxAB Efflux pumps in Antimicrobial Resistance of Clinical isolates of Klebsiella pneumonia. J Appl Biotechnol Rep. 2020;7:251–7. https://doi.org/10.30491/JABR.2020.120179

    Article  CAS  Google Scholar 

  23. Aditi Priyadarshini B, Mahalakshmi K, Kumar N. V.Mutant prevention concentration of ciprofloxacin against Klebsiella pneumoniae clinical isolates: an ideal prognosticator in treating multidrug-resistant strains. Int J Microbiol. 2019. https://doi.org/10.1155/2019/6850108

    Article  PubMed  PubMed Central  Google Scholar 

  24. Esmaeel NE, Gerges MA, Hosny TA, Ali AR, Gebriel MG. Detection of chromosomal and plasmid-mediated quinolone resistance among Escherichia coli isolated from urinary tract infection cases; Zagazig University Hospitals, Egypt. Infect Drug Resist. 2020;413–21. https://doi.org/10.2147/IDR.S240013

  25. Geetha PV, Aishwarya KVL, Mariappan S, Sekar U. Fluoroquinolone resistance in clinical isolates of Klebsiella pneumoniae. J Lab Physicians. 2020;12:121–5. https://doi.org/10.1055/s-0040-1716478

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sani GS, Ghane M, Babaeekhou L. Fluoroquinolone-resistance mechanisms and molecular epidemiology of ciprofloxacin-resistant Klebsiella pneumoniae isolates in Iran. Folia Microbiol. 2023;1–12. https://doi.org/10.1007/s12223-023-01042-2

  27. Akya A, C Lorestani R, Elahi A, Ghadiri K. The impact of mutations in topoisomerase genes and the plasmid-mediated quinolone resistance (PMQR) determinants on the resistance to fluoroquinolones in Klebsiella pneumoniae. Arch Clin Infect Dis. 2017;12. https://doi.org/10.5812/archcid.57290

  28. Shams E, Firoozeh F, Moniri R, Zibaei M. Prevalence of plasmid-mediated quinolone resistance genes among extended-spectrum β-Lactamase-producing Klebsiella pneumoniae human isolates in Iran. J Pathog. 2015. https://doi.org/10.1155/2015/434391

    Article  PubMed  PubMed Central  Google Scholar 

  29. Fu Y, Guo L, Xu Y, Zhang W, Gu J, Xu J, Chen X, Zhao Y, Ma J, Liu X. Alteration of GyrA amino acid required for ciprofloxacin resistance in Klebsiella pneumoniae isolates in China. Antimicrob Agents Chemother. 2008;52:2980–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Anuar AS, Yusof MM, Tay S. Prevalence of plasmid-mediated qnr determinants and gyrase alteration in Klebsiella pneumoniae isolated from a university teaching hospital in Malaysia. Eur Rev Med Pharmacol Sci. 2013;17:1744–7.

    Google Scholar 

Download references

Acknowledgements

We would like to thank Clinical Research Development Center, The Persian Gulf Martyrs Hospital, Bushehr University of Medical Sciences, Bushehr, Iran for facilitating the process of sampling.

Funding

This article was from the postgraduate MSc thesis of Sepideh Rezaei and was supported by the Vice-Chancellor of Research of Bushehr University of Medical Sciences, Bushehr, Iran (grant no. 1898).

Author information

Authors and Affiliations

  1. Department of Microbiology and Parasitology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

    Sepideh Rezaei, Saeed Tajbakhsh, Behrouz Naeimi & Forough Yousefi

  2. Student Research Committee, Bushehr University of Medical Sciences, Bushehr, Iran

    Sepideh Rezaei

Authors
  1. Sepideh Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saeed Tajbakhsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Behrouz Naeimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Forough Yousefi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by FY, ST, SR and BN. The first draft of the manuscript was written by FY and all authors read, edited and approved the final manuscript.

Corresponding author

Correspondence to Forough Yousefi.

Ethics declarations

Ethics approval and consent to participate

Based on the rules of the Ethical Committee of our institute, this study did not require informed consent statement, because all isolates were recovered from clinical specimens during routine diagnostic procedures and these isolates were not specific to this study. In addition, the patients were not available to us. Based on the points mentioned above, the Ethical Committee of Bushehr University of Medical Sciences approved our project with reference number IR.BPUMS.REC.1400.133 and allowed this study to be conducted without informed consent statement.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rezaei, S., Tajbakhsh, S., Naeimi, B. et al. Investigation of gyrA and parC mutations and the prevalence of plasmid-mediated quinolone resistance genes in Klebsiella pneumoniae clinical isolates. BMC Microbiol 24, 265 (2024). https://doi.org/10.1186/s12866-024-03383-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12866-024-03383-5

Keywords

BMC Microbiology

ISSN: 1471-2180

Contact us